Transrectal Implantation Of ¹²⁵ Ⅰ Particles In The Treatment Of Prostate Cancer

bjective: Prostate cancer(PCa) as men in many Western countries, the most common malignancy, accounting for U.S. men in 2006 the second cause of cancer death. Since prostate-specific antigen (PSA) examination started, since the early 90s to mid-century found significantly higher incidence of PCa. Although the low incidence of PCa, but in recent years as the population ages and the improvement of living conditions, the incidence rate increased rapidly, in our male urinary and reproductive system cancer incidence rates in the ranks third. PCa has become of our men, especially men over 50 years of age an important factor in health, due to occult PCa incidence and the current inspection of PSA is not yet universal primary health care sector, so most of the time already in advanced PCa detection, to clinical treatment with to the difficulty, so how to choose the best treatment is our common goal. Recent years, with new, low energy, safe, easy protection for the successful development of radionuclides ¹²⁵I, real-time positioning accuracy of transrectal ultrasound, CT imaging technology matures and computer three-dimensional radiotherapy treatment planning system emerges, the radioactive nuclide implantation in the treatment of various tumors received wide attention and conduct, especially in the application of the treatment of prostate cancer may be more mature. But the way in terms of implantation of radioactive particles in research are rarely at home and abroad, have not been reported after implantation of the rectum. Therefore, this research means the implantation of radioactive particles through the rectum and the feasibility and safety of brachytherapy for prostate cancer provides a new method of approach and thinking. Methods : In the present study on the Mianyang Central Hospital from March 2006 to May 2010 were treated 82 patients with prostate cancer were divided into experimental and control groups. Experimental group of 42 patients with prostate cancer research prostate volume; through the treatment planning system (Treaetment Plan System, TPS) plans; Using transrectal ultrasound (Transrectal Ultrasonography, TRUS) guided transrectal prostate biopsy will be the implementation of ¹²⁵I seed implantation treatment programs, and also underwent bilateral orchiectomy treatment; after scanning of spiral CT to determine the distribution of particles and for dose distribution assessment Regular follow-up treatment and complications. The implementation of the control group, 40 patients with bilateral orchiectomy. While 82 cases of patients taking bicalutamide endocrine chemotherapy. Results: Experimental group, 42 patients successfully completed surgery, were followed up for 24-48 months, with a median follow-up time of 36.6 months. Experimental group, 42 patients successfully completed surgery, implantation of particles 22 (10-50) teeth, no Transrectal puncture caused by serious complications; after the use of CT scanning, see particle distributions in the schedule; dose distribution assessment of satisfaction. 1 case occurred 16 months after bone metastases, and 2 cases occurred after an average of 18.6 months PSA biochemical recurrence, patients with total PSA progression-free survival rate was 92.8%. Control group, 1 patient died 23 months after operation, 3 cases occurred in the 14 months after bone metastases, 5 patients in an average of 15.8 months after biochemical recurrence of PSA occurred, the cumulative PSA progression-free survival rate was 77.5% of patients . Conclusion: By TRUS-guided transrectal implantation of ¹²⁵I radioactive particle technology and joint surgical castration simple and efficient treatment of locally advanced prostate cancer is a safe and effective treatment.